Trial Profile
30-day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Acenocoumarol; Enoxaparin sodium
- Indications Thromboembolism; Venous thrombosis
- Focus Adverse reactions
- Acronyms EINSTEINJunior
- Sponsors Bayer
- 13 Oct 2016 Status changed from active, no longer recruiting to completed.
- 12 Oct 2016 This trial was completed in Germany (end date: 2016-09-01).
- 31 Aug 2016 This trial has been completed in Austria as per European Clinical Trials Database record.